首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   35174篇
  免费   2765篇
  国内免费   348篇
耳鼻咽喉   385篇
儿科学   976篇
妇产科学   954篇
基础医学   4482篇
口腔科学   588篇
临床医学   3626篇
内科学   7467篇
皮肤病学   827篇
神经病学   2360篇
特种医学   1306篇
外科学   4836篇
综合类   1149篇
一般理论   32篇
预防医学   1869篇
眼科学   1559篇
药学   2692篇
  2篇
中国医学   306篇
肿瘤学   2871篇
  2023年   239篇
  2022年   178篇
  2021年   717篇
  2020年   600篇
  2019年   753篇
  2018年   980篇
  2017年   760篇
  2016年   854篇
  2015年   1036篇
  2014年   1368篇
  2013年   1635篇
  2012年   2340篇
  2011年   2451篇
  2010年   1408篇
  2009年   1238篇
  2008年   1912篇
  2007年   2005篇
  2006年   1991篇
  2005年   1925篇
  2004年   1701篇
  2003年   1584篇
  2002年   1419篇
  2001年   1112篇
  2000年   1050篇
  1999年   890篇
  1998年   343篇
  1997年   250篇
  1996年   234篇
  1995年   215篇
  1994年   208篇
  1993年   209篇
  1992年   457篇
  1991年   444篇
  1990年   426篇
  1989年   425篇
  1988年   363篇
  1987年   391篇
  1986年   336篇
  1985年   299篇
  1984年   215篇
  1983年   157篇
  1982年   99篇
  1981年   93篇
  1980年   100篇
  1979年   142篇
  1978年   92篇
  1977年   84篇
  1976年   83篇
  1975年   77篇
  1972年   69篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
急性梗阻性化脓性胰管炎在临床上十分罕见,本文报道1例慢性胰腺炎合并急性梗阻性化脓性胰管炎,并在此基础上继发假性囊肿感染的病例,分析了假性囊肿感染的原因,并探讨了内镜治疗及抗感染治疗的策略与挑战。  相似文献   
2.
Ding  Fangfang  Huang  Jie  Feng  Zeying  Kuang  Yun  Yang  Shuang  Xiang  Yuxia  Zou  Chan  Yang  Guoping 《Investigational new drugs》2022,40(3):606-613
Investigational New Drugs - Purpose. This study aimed to compare the safety, tolerability, pharmacokinetics (PK), and bioequivalence of a test humanized recombinant monoclonal antibody targeting...  相似文献   
3.
Ma  Junlong  Chen  Wenjing  Hu  Zhanqing  Huang  Jie  Guo  Chengxian  Zou  Chan  Yang  Guoping 《Investigational new drugs》2022,40(4):861-867
Investigational New Drugs - Pertuzumab is a recombinant anti-HER2 humanized monoclonal antibody widely used for the adjuvant treatment of HER2-positive breast cancer. Its safety is well established...  相似文献   
4.
BackgroundThe purpose of this study is to determine the comparative risk profile and clinical outcomes for patients undergoing reverse total shoulder arthroplasty (RTSA) for cuff tear arthropathy (CTA) without failed prior rotator cuff repair (RCR) compared with RTSA for CTA with prior RCR.MethodsFrom 2006 to 2014, all patients who underwent RTSA by two surgeons after failed RCR with minimum 2-year follow-up were identified. Patients who underwent RTSA with failed prior RCR were matched in a 1:1 ratio to patients undergoing primary RTSA, while controlling for demographic factors, prosthesis design, and surgeon. Postoperative active forward elevation and active external rotation were recorded. Outcome measures included American Shoulder and Elbow Surgeons score, Visual Analog Scale (VAS), and Simple Shoulder Test. Perioperative complications and rates of secondary reoperation were noted, and comparative multivariate analysis was performed.ResultsOf 262 patients, 192 (73.3%) were available at minimum 2-year follow-up. The prior RCR group had a significantly higher complication rate (17.4%, n = 15) than the primary RTSA group (3.8%, n = 4) (P = .001), although no significant difference in periprosthetic infection (P = .469) or secondary revision rate (P = .136) was observed. At mean 36.3 ± 26.1-month follow-up, the prior RCR group had statistically worse American Shoulder and Elbow Surgeons score (P < .001), VAS (P = .001), Simple Shoulder Test (P < .001), and active forward elevation (P = .006). Patients with multiple failed RCR attempts (n = 38) before RTSA demonstrated no significant differences versus isolated failed RCR (n = 48; P > .05).ConclusionThis study demonstrated that patients with RTSA after prior failed RCR have significantly worse patient-reported outcomes and greater rate of perioperative complications than patients undergoing primary RTSA for CTA.  相似文献   
5.
6.
7.
8.
The International Journal of Cardiovascular Imaging - Early detection of acute cellular rejection (ACR) by echocardiography shows potential clinical benefit as ACR remains a significant contributor...  相似文献   
9.
10.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号